HTG’s 1:1 Promise Cdx Partnerships, Personalized.
HTG will be at the 2018 ASCO Annual Meeting. Stop by and learn how our NGS-based HTG EdgeSeq chemistry and automation can help shape the future of oncology.
McCormick Place | Chicago, IL | June 1 - June 5 | Booth #4113 | Meeting Room MR1 on Exhibit Hall Floor
Join us Friday, June 02, 2017 through Tuesday, June 06, 2017 at McCormick Place in Chicago, IL.
HTG will be at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. Stop by and learn how our NGS-based HTG EdgeSeq chemistry and automation can help shape the future of oncology.
Join us Thursday, February 23, 2017 through Saturday, February 25, 2017 in Orlando, Fl.
Visit HTG at booth #3 at the ASCO-SITC meeting to learn how we are enabling drug development from discovery to clinic with our universal CDx NGS-based multiplexed profiling panels, extraction-free NGS-based chemistry and our NGS-based automation, the HTG EdgeSeq system.
TUCSON, Ariz. and LOS ANGELES, June 06, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications, and Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the acceptance of a study by the American Society of Clinical Oncology (ASCO) for presentation at their 2016 Annual Meeting, June 3–7, 2016 in Chicago, IL.
Page last updated March 20, 2023